ClinicalTrials.gg
Not yet recruitingNCT07470177Updated Mar 13, 2026

A Study to Investigate the Effects of JMKX003142 on QTc Interval in Healthy Adults

A Phase 1 interventional study of JMKX003142 tablets and JMKX003142 tablets in ADPKD (Autosomal Dominant Polycystic Kidney Disease), sponsored by Jemincare. Not yet recruiting. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-13.

Sponsored by Jemincare · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The primary objective of this study is to assess the effect of a therapeutic and supratherapeutic oral dose of JMKX003142 on the corrected cardiac QT interval relative to a placebo in healthy participants

02

Conditions studied

  • ADPKD (Autosomal Dominant Polycystic Kidney Disease)
03

In context

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

This study's planned enrollment of 24 is below the median of 51 across 138 interventional studies indexed under Polycystic Kidney, Autosomal Dominant.

Browse Polycystic Kidney, Autosomal Dominant studies →

Lead sponsor

Jemincare is the lead sponsor of 37 studies on the registry; 30 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must be able to return to the study center for follow-up visits as required by the protocol and be willing to comply with study policies, procedures, and constraints. They must be able to communicate effectively with the investigator, complete study-related materials, and understand the contents of the Form (ICF). A written ICF must be signed before any study-specific procedures are performed.
  2. Healthy Chinese males or females based on medical history and physical examination. At the time of signing the informed consent form (ICF), participants must be aged 18 to 45 years (inclusive), with a body weight ≥ 50 kg and a (BMI) between 19.0 and 28.0 $kg/m\^2 (inclusive).
  3. Participants' health status will be determined by the investigator based on medical history, physical examination, clinical laboratory tests, and 12-lead (ECG). All test results must be confirmed by the investigator as either normal or abnormal without clinical significance (NCS).
  4. Participants of must have no plans to conceive, freeze, or donate sperm/eggs from the time of signing the informed consent form (ICF) until 3 months after the last dose, and must agree to use highly effective methods.

Exclusion criteria

Exclusion Criteria:

  1. History or presence of diseases, including but not limited to: cardiovascular, respiratory, gastrointestinal, hematological, genitourinary, endocrine and metabolic, neurological, psychiatric, musculoskeletal, dermatological, lymphatic, or immunological systems, or diseases of the sense organs, as well as current systemic or local acute/chronic infections.
  2. Participants with any condition that increases the risk of bleeding, such as acute gastritis or active ulcers with bleeding, clinically significant thrombocytopenia or anemia, active pathological bleeding, or a history of intracranial hemorrhage.
  3. Vital signs at screening that meet any of the following criteria: systolic blood pressure (SBP) ≥ 140 mmHg or \< 90 mmHg; diastolic blood pressure (DBP) ≥ 90 mmHg or \< 50 mmHg; pulse rate > 100 bpm or \< 50 bpm; or axillary temperature > 37.2°C.
  4. History of prolongation, or any clinically significant abnormal findings at screening as determined by the investigator, or QTcF ≥ 450 ms, or QRS duration > 120 ms, or PR interval ≥ 200 ms.
  5. Clinical laboratory test results at screening showing serum potassium, magnesium, or calcium levels outside the normal range and judged by the investigator to be clinically significant.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Part 1

    Drug: JMKX003142 tablets · Drug: Placebo

  • Experimental
    Part 2

    Drug: JMKX003142 tablets · Drug: Placebo

Interventions

  • Participants will receive single of JMKX003142 6mg

  • Participants will receive single of JMKX003142 30mg

  • DrugPlacebo

    Participants will receive single of Placebo

06

What researchers measure

Primary outcomes

  1. The effect of JMKX003142 treatment on placebo-corrected change from baseline QT interval (ΔΔQTc)

    Time frame: Up to 24 hours post dose

Secondary outcomes

  1. Placebo-corrected Change From Baseline in Heart Rate After JMKX003142 treatment

    Time frame: Up to 72 hours post dose

  2. Placebo-corrected Change From Baseline in QRS after JMKX003142 treatment

    Time frame: Up to72 hours post dose

  3. Placebo-corrected Change From Baseline in PR Interval After JMKX003142 treatment

    Time frame: Up to 72 hours post dose

  4. Number of Participants With Treatment-emergent Changes in T-wave Morphology and U-wave Presence

    Time frame: Up to 72 hours post dose

  5. Incidence of adverse events to assess the safety of single-dose administration of JMKX003142

    Time frame: Up to 72 hours post dose

  6. Maximum Observed Plasma Concentration (Cmax) of JMKX003142

    Time frame: Up to 72 hours post dose

  7. Time to Maximum Observed Plasma Concentration (Tmax) of JMKX003142

    Time frame: Up to 72 hours post dose

  8. Apparent Terminal Elimination Half-life (T1/2) of JMKX003142

    Time frame: Up to 72 hours post dose

  9. Area Under the Concentration-time Curve From Time 0 to the Time of Last Quantifiable Concentration (AUC0-t) for JMKX003142

    Time frame: Up to 72 hours post dose

  10. AUC From Time 0 to Infinity (AUCinf) for JMKX003142

    Time frame: Up to 72 hours post dose

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2026; primary completion for May 2026, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2026
First posted
Mar 13, 2026
StartEst.
Mar 27, 2026
Primary completionEst.
May 14, 2026
CompletionEst.
Jun 23, 2026
Last update
Mar 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07470177
Lead sponsor
Jemincare
Collaborators
Zhejiang Hangyu Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Mar 13, 2026
Start date
Mar 27, 2026 (estimated)
Primary completion
May 14, 2026 (estimated)
Completion
Jun 23, 2026 (estimated)
Last update
Mar 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JMKX003142

Start the discussion